TL;DR
This study investigates the long-term safety of splenectomy for immune thrombocytopenia (ITP), finding it's an independent risk factor for venous thromboembolism (VTE) and severe infections. Despite these risks, splenectomy remains an effective treatment for ITP, with similar overall survival and malignancy rates compared to non-splenectomized patients.
What Problem Does This Paper Address?
Immune thrombocytopenia (ITP) is a bleeding disorder where the body's immune system attacks its own platelets. Historically, splenectomy (surgical removal of the spleen) was a go-to treatment for chronic, severe ITP because the spleen is a major site of platelet destruction and antibody production. However, with the advent of newer drugs like rituximab and thrombopoietin-receptor agonists (Tpo-Ras), the use of splenectomy has declined. This shift is partly due to lingering questions about the long-term safety of splenectomy, particularly concerning risks like severe infections (overwhelming postsplenectomy infections or OPSI) and blood clots (venous thromboembolism or VTE). This paper aims to provide much-needed data on these long-term complications by comparing a cohort of ITP patients who underwent splenectomy with a matched cohort who did not.
Methods
The researchers conducted a single-center, exposed/unexposed cohort study. They identified 83 adult patients with primary ITP who had undergone splenectomy more than 10 years prior. These "exposed" patients were then meticulously matched with 83 "unexposed" ITP patients who had not had their spleen removed. The matching criteria were crucial for ensuring a fair comparison: the date of ITP diagnosis (within a 5-year window), age at diagnosis, and gender.
Data collection was retrospective, drawing from medical charts and supplemented by phone interviews with patients and their physicians. They defined "response" to splenectomy based on platelet counts. Clinical outcomes, including venous thromboembolism (VTE), cardiovascular (CV) events, infections, and malignancies, were systematically tracked. Statistical analysis involved Fisher exact tests, Mann-Whitney tests, Kaplan-Meier survival analysis, and Cox proportional hazards models to identify independent risk factors. A propensity score was also used to further adjust for potential confounding factors.
Datasets
Not discussed in the paper. The study utilized retrospective data from patients treated at a single French university hospital.
Key Insights and Ideas
- Splenectomy as an Independent VTE Risk: The most striking finding is that splenectomy itself appears to be an independent risk factor for VTE, even after accounting for other known risk factors and the underlying ITP disease. This suggests a direct physiological impact of spleen removal on thrombotic risk.
- Severe Infections Remain a Concern: While the overall incidence of infection didn't differ significantly, splenectomized patients experienced more severe infections that all required hospitalization. A concerning proportion of these led to severe sepsis or septic shock, with some fatalities. This highlights the spleen's critical role in immune defense against encapsulated bacteria.
- Cardiovascular Risk More Linked to ITP: Interestingly, the study suggests that cardiovascular risk might be more closely tied to the ITP disease itself rather than the splenectomy. This is a crucial distinction for patient management.
- No Increased Cancer Risk: The study found no significant difference in malignancy rates between the splenectomized and control groups, offering reassurance on this front.
- Overall Survival Unaffected: Despite the increased risks of VTE and severe infections, splenectomy did not significantly decrease overall survival in the long term.
Key Results
- VTE: 16% of splenectomized patients experienced at least one VTE, compared to only 2% of controls (P=0.005). Splenectomy was an independent risk factor for VTE (HR=4.01, P=0.032).
- Infections: All infections in splenectomized patients required hospitalization. 19% of infections in this group led to severe sepsis or septic shock, resulting in death for 3 patients (none in controls).
- Cardiovascular Events: 12% of splenectomized patients had CV events vs. 5% of controls (P=0.143), but this difference was not statistically significant and appeared related to ITP rather than splenectomy.
- Malignancies: 14% of splenectomized patients and 12% of controls developed cancer (P=0.789).
- Overall Survival: The number of deaths did not differ significantly between groups (20% vs. 11%, P=0.206).
- Response Rate: 52% of splenectomized patients achieved a long-term sustained response to the surgery.
Limitations and Future Work
The primary limitation acknowledged is the retrospective nature of the study, which can lead to missed data. However, the authors mitigated this by meticulously reviewing charts and conducting extensive interviews. They also note that the study's size, while substantial for a single-center cohort, might limit definitive conclusions on less frequent events like CV disease and cancer.
Future work should focus on improving preventive measures for VTE and severe infections, including enhanced vaccination protocols and patient education on OPSI risks. Further research into the mechanisms linking splenectomy to VTE is warranted. The authors also suggest that while splenectomy remains effective, the decision to proceed should carefully weigh these long-term risks against the benefits, especially with the availability of new medical therapies.
Summary updated